Study of XB010 in Subjects With Solid Tumors
Recruiting now · Phase 1
Conditions studied: Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC)
In brief
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.
Key facts
- Study ID
- NCT06545331
- Run by
- Exelixis
- People needed
- 396
- Starts
- 2024-08-06
- Expected to finish
- 2027-10-20
- Last updated by the study team
- 2026-06-22
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California, United States (enrolling)
- UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California, United States (enrolling)
- Georgetown University Medical Center — Washington D.C., District of Columbia, United States (enrolling)
- Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando, Florida, United States (enrolling)
- Winship Cancer Institute — Atlanta, Georgia, United States (enrolling)
- University of Chicago Medical Center — Chicago, Illinois, United States (enrolling)
- Siteman Cancer Center — St Louis, Missouri, United States (enrolling)
- Montefiore Medical Center - Montefiore Medical Park — The Bronx, New York, United States (enrolling)
- Carolina BioOncology Institute — Huntersville, North Carolina, United States (enrolling)
- Stephenson Cancer Center — Oklahoma City, Oklahoma, United States (enrolling)
- SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
- NEXT Austin — Austin, Texas, United States (enrolling)
- Baylor University Medical Center — Dallas, Texas, United States (enrolling)
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Inova Schar Cancer — Fairfax, Virginia, United States (enrolling)
- NEXT Virginia — Fairfax, Virginia, United States (enrolling)
- University Hospitals of Leicester NHS Trust — Leicester, United Kingdom (enrolling)
- Sarah Cannon Research Institute London — London, United Kingdom (enrolling)
- University College London Hospitals NHS Foundation Trust — London, United Kingdom (enrolling)
- The Christie NHS Foundation Trust — Manchester, United Kingdom (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.